Health & Fitness
Health and Fitness
Health and Fitness
Thu, August 2, 2012
Wed, August 1, 2012
Trimel Pharmaceuticals Corporation to Report Second Quarter 2012 Results and Host a Conference Call to Update Investors
August 01, 2012 15:21 ET
Trimel Pharmaceuticals Corporation to Report Second Quarter 2012 Results and Host a Conference Call to Update Investors
TORONTO, ONTARIO--(Marketwire - Aug. 1, 2012) - Trimel Pharmaceuticals Corporation (TSX:TRL) (the "Company" or "Trimel") will report on the second quarter financial results for the Company and its subsidiaries for the period ended June 30, 2012 on Tuesday August 7, 2012 after the market closes.
Management of the Company will host a conference call to discuss these results and update investors on the status of its business on Wednesday, August 8, 2012, at 8:30 a.m. Eastern Daylight Time. Presenting from Trimel will be Bruce Brydon, Chairman of the Board and Chief Executive Officer, Tom Rossi, President and Chief Operating Officer and Kenneth Howling, Chief Financial Officer.
To access the call live, please dial 416-340-2216 (Toronto), 1-866-226-1792 (Canada and U.S.), and 00-800-9559-6849 (International). Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays.
A replay of the conference call will be available until 7:00 p.m. Eastern Time on Tuesday, August 14, 2012 by dialing 905-694-9451 (Toronto), 1-800-408-3053 (Canada and U.S.) or 00-800-3366-3052 (International), using access code: 2484026#.
For further information regarding Trimel Pharmaceuticals Corporation, please contact either Bruce Brydon, Chairman of the Board and Chief Executive Officer at (416) 679-0711 or Kenneth Howling, Chief Financial Officer at (416) 679-0536 or via email at [ ir@trimelpharmaceuticals.com ].
About Trimel
Trimel Pharmaceuticals Corporation (TSX:TRL) - Developing medications for Female Sexual Health and conditions related to Aging, and Well Being. Trimel is developing multiple product opportunities, including CompleoTRT™, a bio-adhesive intranasal Testosterone gel currently in Phase III clinical testing in the United States. CompleoTRT™ is under investigation for the treatment of male hypogonadism, a condition commonly referred to as "Low T". For more information, please visit [ www.trimelpharmaceuticals.com ].
